Segment
Research tools: reading, editing and measuring biology
Behind every therapeutic programme is a set of instruments and reagents that read genomes, edit them and measure what happened. It is a business with better economics than drug development, because it sells to everyone regardless of whose drug works.
In one sentence
Research tools are the instruments, reagents and consumables used to sequence nucleic acids, edit genomes and analyse biological samples in research and clinical settings.
The commercial pattern is consistent: an instrument sold at modest margin, and proprietary consumables sold for its life at high margin. That installed-base model is why these businesses are more stable than the therapeutics they serve, and why competition centres on cost per sample rather than on instrument price.
The scientific pattern is that cost curves change what questions get asked. Sequencing a genome fell in price by orders of magnitude faster than semiconductors improved, and each fall enabled a category of work that had been impossible — population studies, single-cell analysis, routine clinical sequencing.
How this breaks down
Split by what the tool does to the sample: reads it, changes it, or measures it.
- Research toolsthis page
- DNA sequencingShort reads, long reads, flow cells and the semiconductor manufacturing behind them.Definition pageChokepoint
- Gene editingCRISPR, base and prime editing, and why delivery rather than cutting is the hard part.Definition pageChokepoint
- Analytical instrumentsMass spectrometry, chromatography and the characterisation that regulatory filings rest on.Definition pageChokepoint
What this depends on
1 of these is marked as a chokepoint: a handful of qualified suppliers, a multi-year lead time, or a single geography.
- Supply chainChokepoint
Enzymes and reagents
Every method consumes proprietary enzyme and reagent chemistry, which is where the recurring revenue sits.
Media and reagents - Resource
Research and capital budgets
Instrument demand tracks academic, biotech and pharma capital spending, and a funding downturn shows up as deferred instrument purchases long before it shows up in consumables.
Companies across Research tools
Every company named on a step below this page, ordered by how many of those steps it appears at. Compiled from the pages themselves rather than written separately, so the two cannot disagree. Not a ranking and not a recommendation.
- MGI TechShanghai1 step
7 more companies appear at a single step each; they are named on the pages for those steps.
How these pages are written
Each page explains one technology in plain language, states what it depends on, and names companies by what they supply at that step. Company roles are described qualitatively and deliberately carry no market shares, revenue figures or rankings — those change faster than an explainer can, and a stale number is worse than none. Ticker links point at company pages on this site and are provided for reference only.
Nothing here is investment advice, a recommendation, or a forecast. A company named on a page about a technology is not thereby a good investment, and the chokepoints described are structural facts about supply chains rather than predictions about prices. Technology moves; where a page describes something as unresolved or in development, that was true when it was written.
Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal